CH7233163 T35334

Product Introduction
Bioactivity


英文名: CH7233163

描述: CH7233163 是一种EGFR-tyrosine kinase 的非共价ATP 竞争性抑制剂，对有EGFR-Del19/T790M/C797S 的肿瘤具有抗肿瘤活性。

细胞实验: Cell lines: NIH3T3 cells (ATCC)Concentrations: 8 nM, 40 nM, 200 nM, 1000 nMIncubation Time: 0.5 h-24 h, 4-7 daysMethod: NIH3T3 cells (ATCC) are transduced with lentiviruses harboring genes encoding the EGFR-d746-750/T790M/C797S or EGFR-L858R/T790M/C797S mutant, generated from the pCDH-CMV-MCS-EF1-Puro vector. Cells stably expressing these mutants are subsequently selected in medium supplemented with puromycin. Cells are incubated in medium containing serial dilutions of CH7233163 in a 96-well culture plate or PrimeSurface96U plates at 37?C for 4 or 7 d. The number of living cells is then determined using CellTiter-Glo 9 Luminescent Cell Viability Assay.

体外活性: CH7233163 shows potent antitumor activities against tumor with EGFR-Del19/T790M/C797S in vitro. CH7233163 potently inhibits the proliferation of Del19/T790M/C797S_NIH3T3 cells with IC50 of 20 nmol/L. CH7233163 potently and dose-dependently blocks the EGFR phosphorylation in the Del19/T790M/C797S_NIH3T3 cells. CH7233163 can inhibit Del19/T790M/C797S signaling.[1]

体内活性: Pharmacodynamic study is performed using Del19/T790M/C797S_NIH3T3 xenografted tumors in mice. CH7233163 clearly inhibits EGFR phosphorylation after oral administration and potent tumor regression is observed. CH7233163 has potent therapeutic efficacy against tumors with EGFR-Del19/T790M/C797S in vivo.[1]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: CH 7233163 | CH7233163 | CH-7233163

相关产品: AG-1478 | Avitinib maleate | Theliatinib | Nuvenzepine | AG1557 | EGFR/CDK2-IN-4 | BLU-945 | AZD3759 hydrochloride | Poziotinib hydrochloride | EMI1

CH7233163 T35334信息由TargetMol中国为您提供，如您想了解更多关于CH7233163 T35334报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途